MPLT vs TERN

Analysts rate Terns Pharmaceuticals, Inc.

(TERN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Terns Pharmaceuticals, Inc.

(TERN) delivered a total return of +232. 8%, compared to +62. 6% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: TERN returned +187. 9% versus MPLT's +59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

On balance sheet safety, Terns Pharmaceuticals, Inc.

(TERN) carries a lower debt/equity ratio of 0% versus 6% for MapLight Therapeutics, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Terns Pharmaceuticals, Inc.

grew EPS 8. 0% year-over-year, compared to -39. 6% for MapLight Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MapLight Therapeutics, Inc.

(MPLT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Terns Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MPLT leads at 0. 0% versus 0. 0% for TERN. At the gross margin level — before operating expenses — MPLT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Terns Pharmaceuticals, Inc.

(TERN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 44), +187. 9% 10Y return). Both have compounded well over 10 years (TERN: +187. 9%, MPLT: +59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.